Seminars in Hematology
Volume 40, Issue 1 , Pages 50-58 , January 2003

Imatinib alone and in combination for chronic myeloid leukemia

References 

  1. Beran M, Cao X, Estrov Z, et al.  Selective inhibition of cell proliferation and BCR-ABL phosphorylation in acute lymphoblastic leukemia cells expressing Mr 190,000 BCR-ABL protein by a tyrosine kinase inhibitor (CGP-57148). Clin Cancer Res. 1998;4:1661–1672
  2. Branford S, Rudzki Z, Walsh S, et al.  High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance. Blood. 2002;99:3472–3475
  3. Buchdunger E, Matter A, Druker BJ. Bcr-Abl inhibition as a modality of CML therapeutics. Biochim Biophys Acta. 2001;1551:M11–M18
  4. Carroll M, Ohno-Jones S, Tamura S, et al.  CGP 57148, a tyrosine kinase inhibitor, inhibits the growth of cells expressing BCR-ABL, TEL-ABL and TEL-PDGFR fusion proteins. Blood. 1997;90:4947–4952
  5. Deininger MW, Goldman JM, Lydon N, et al.  The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL-positive cells. Blood. 1997;90:3691–3698
  6. Demetri GD, von Mehren M, Blanke CD, et al.  Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med. 2002;347:472–480
  7. Dorsey JF, Jove R, Kraker AJ, et al.  The pyrido(2,3-d)pyrimidine derivative PD180970 inhibits p210Bcr-Abl tyrosine kinase and induces apoptosis of K562 leukemic cells. Cancer Res. 2000;60:3127–3131
  8. Druker B, Kantarjian H, Talpaz M, et al.  A phase I study of the combination of gleevec (imatinib mesylate) with low dose Ara-C. Blood. 2001;98(suppl 1, abstr):845a
  9. Druker BJ, for the IRIS International Randomized IFN vs. STI571 Study Group . STI571 (Gleevec/Glivec, imatinib) versus interferon (IFN) + cytarabine as initial therapy for patients with CML: Results of a randomized study. Proc Am Soc Clin Onc. 2002;21:1a; (abstr)
  10. Druker BJ, Lydon NB. Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia. J Clin Invest. 2000;105:3–7
  11. Druker BJ, Sawyers CL, Capdeville R, et al.  Chronic myelogenous leukemia. Hematology (Am Soc Hematol Educ Program). 2001;87–112
  12. Druker BJ, Sawyers CL, Kantarjian H, et al.  Activity of a specific inhibitor of the Bcr-Abl tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med. 2001;344:1038–1042
  13. Druker BJ, Talpaz M, Resta D, et al.  Efficacy and safety of a specific inhibitor of the Bcr-Abl tyrosine kinase in chronic myeloid leukemia. N Engl J Med. 2001;344:1031–1037
  14. Druker BJ, Tamura S, Buchdunger E, et al.  Effects of a selective inhibitor of the ABL tyrosine kinase on the growth of BCR-ABL positive cells. Nat Med. 1996;2:561–566
  15. Fang G, Kim CN, Perkins CL, et al.  CGP57148B (STI-571) induces differentiation and apoptosis and sensitizes Bcr-Abl-positive human leukemia cells to apoptosis due to antileukemic drugs. Blood. 2000;96:2246–2253
  16. Gambacorti-Passerini C, le Coutre P, Mologni L, et al.  Inhibition of the ABL kinase activity blocks the proliferation of BCR/ABL+ leukemic cells and induces apoptosis. Blood Cells Mol Dis. 1997;23:380–394
  17. Gatto SR, Scappini B, Verstovsek S, et al.  In vitro effects of PS-341 alone and in combination with STI571 in Bcr-Abl positive cell lines both sensitive and resistant to STI571. Blood. 2001;98(suppl 1, abstr):101a
  18. Graham SM, Jorgensen HG, Allan E, et al.  Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. Blood. 2002;99:319–325
  19. Hochhaus A, Kreil S, Corbin AS, et al.  Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy. Leukemia. 2002;16:2190–2196
  20. Hofmann WK, Jones LC, Lemp NA, et al.  Ph(+) acute lymphoblastic leukemia resistant to the tyrosine kinase inhibitor STI571 has a unique BCR-ABL gene mutation. Blood. 2001;99:1860–1862
  21. Holtz MS, Slovak ML, Zhang F, et al.  Imatinib mesylate (STI571) inhibits growth of primitive malignant progenitors in chronic myelogenous leukemia through reversal of abnormally increased proliferation. Blood. 2002;99:3792–3800
  22. Hoover RR, Mahon FX, Melo JV, et al.  Overcoming STI571 resistance with the farnesyl transferase inhibitor SCH66336. Blood. 2002;100:1068–1071
  23. Kano Y, Akutsu M, Tsunoda S, et al.  In vitro cytotoxic effects of a tyrosine kinase inhibitor STI571 in combination with commonly used antileukemic agents. Blood. 2001;97:1999–2007
  24. Kantarjian H, Jorge C, O'Brien S, et al.  High rates of early major and complete cytogenetic responses with imatinib mesylate therapy given at 400 mg or 800 mg orally daily in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase. Proc Am Soc Clin Oncol. 2002;21:261a; (abstr)
  25. Kantarjian H, Sawyers C, Hochhaus A, et al.  Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med. 2002;346:645–652
  26. Klejman A, Rushen L, Morrione A, et al.  Phosphatidylinositol-3 kinase inhibitors enhance the anti-leukemia effect of STI571. Oncogene. 2002;21:5868–5876
  27. La Rosée P, Johnson K, Moseson EM, et al.  Preclinical evaluation of the efficacy of STI571 in combination with a variety of novel anticancer agents. Blood. 2001;98(suppl 1, abstr):839a
  28. La Rosee P, Johnson K, O'Dwyer ME, et al.  In vitro studies of the combination of imatinib mesylate (Gleevec) and arsenic trioxide (Trisenox) in chronic myelogenous leukemia. Exp Hematol. 2002;30:729–737
  29. La Rosee P, O'Dwyer ME, Druker BJ. Insights from pre-clinical studies for new combination treatment regimens with the Bcr-Abl kinase inhibitor imatinib mesylate (Gleevec/Glivec) in chronic myelogenous leukemia: A translational perspective. Leukemia. 2002;16:1213–1219
  30. le Coutre P, Mologni L, Cleris L, et al.  In vivo eradication of human BCR/ABL-positive leukemia cells with an ABL kinase inhibitor. J Natl Cancer Inst. 1999;91:163–168
  31. Lugo TG, Pendergast AM, Muller AJ, et al.  Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. Science. 1990;247:1079–1082
  32. Marley SB, Davidson RJ, Goldman JM, et al.  Effects of combinations of therapeutic agents on the proliferation of progenitor cells in chronic myeloid leukaemia. Br J Haematol. 2002;116:162–165
  33. Mow BM, Chandra J, Svingen PA, et al.  Effects of the Bcr/abl kinase inhibitors STI571 and adaphostin (NSC 680410) on chronic myelogenous leukemia cells in vitro. Blood. 2002;99:664–671
  34. Nimmanapalli R, Porosnicu M, Nguyen D, et al.  Cotreatment with STI-571 enhances tumor necrosis factor alpha-related apoptosis-inducing ligand (TRAIL or apo-2L)-induced apoptosis of Bcr-Abl-positive human acute leukemia cells. Clin Cancer Res. 2001;7:350–357
  35. O'Brien SG, Vallance SE, Craddock C, et al.  PEGIntron and STI571 combination evaluation study (PISCES) in chronic phase chronic myeloid leukaemia. Blood. 2001;98(suppl 1, abstr):846a
  36. O'Dwyer ME, Mauro MJ, Kurilik G, et al.  The impact of clonal evolution on response to imatinib mesylate (STI571) in accelerated phase CML. Blood. 2002;100:1628–1633
  37. O'Dwyer ME, Mauro MJ, Kuyl J, et al.  Preliminary evaluation of the combination of imatinib mesylate (Gleevec) in combination with low dose interferon-alpha for the treatment of chronic phase CML. Blood. 2001;98(suppl 1, abstr):846a
  38. Okuda K, Weisberg E, Gilliland DG, et al.  ARG tyrosine kinase activity is inhibited by STI571. Blood. 2001;97:2440–2448
  39. Ottmann OG, Druker BJ, Sawyers CL, et al.  A phase II study of imatinib mesylate (Glivec) in patients with relapsed or refractory Philadelphia chromosome positive acute lymphoid leukemias. Blood. 2002;100:1965–1971
  40. Porosnicu M, Nimmanapalli R, Nguyen D, et al.  Co-treatment with As2O3 enhances selective cytotoxic effects of STI-571 against Bcr-Abl-positive acute leukemia cells. Leukemia. 2001;15:772–778
  41. Roche-Lestienne C, Soenen-Cornu V, Grardel-Duflos N, et al.  Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment. Blood. 2002;100:1014–1018
  42. Sawafuji K, Miyakawa Y, Weisberg E, et al.  Effects of aminopeptidase inhibitors on STI571 resistant cell lines. Blood. 2001;98(suppl 1, abstr):309a
  43. Sawyers CL, Hochhaus A, Feldman E, et al.  Imatinib induces hematologic and cytogenetic responses in patients with chronic myeloid leukemia in myeloid blast crisis: Results of a phase II study. Blood. 2002;99:3530–3539
  44. Shah NP, Nicoll JM, Nagar B, et al.  Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell. 2002;2:117–125
  45. Sun X, Layton JE, Elefanty A, et al.  Comparison of effects of the tyrosine kinase inhibitors AG957, AG490, and STI571 on BCR-ABL–expressing cells, demonstrating synergy between AG490 and STI571. Blood. 2001;97:2008–2015
  46. Talpaz M, Silver RT, Druker BJ, et al.  Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: Results of a phase 2 study. Blood. 2002;99:1928–1937
  47. Thiesing JT, Ohno-Jones S, Kolibaba KS, et al.  Efficacy of an Abl tyrosine kinase inhibitor in conjunction with other anti-leukemic agents against Bcr-Abl positive cells. Blood. 2000;96:3195–3199
  48. Topaly J, Schad M, Zeller WJ, et al.  Strong synergism of different signal transduction inhibitors in chronic myelogenous leukemia. Blood. 2001;98(suppl 1, abstr):617a
  49. Topaly J, Zeller WJ, Fruehauf S. Synergistic activity of the new ABL-specific tyrosine kinase inhibitor STI571 and chemotherapeutic drugs on BCR-ABL-positive chronic myelogenous leukemia cells. Leukemia. 2001;15:342–347
  50. van Oosterom AT, Judson I, Verweij J, et al.  Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: A phase I study. Lancet. 2001;358:1421–1423
  51. Vigneri P, Wang JY. Induction of apoptosis in chronic myelogenous leukemia cells through nuclear entrapment of BCR-ABL tyrosine kinase. Nat Med. 2001;7:228–234
  52. von Bubnoff N, Schneller F, Peschel C, et al.  BCR-ABL gene mutations in relation to clinical resistance of Philadelphia-chromosome-positive leukaemia to STI571: A prospective study. Lancet. 2002;359:487–491
  53. Yu C, Krystal G, Varticovksi L, et al.  Pharmacologic mitogen-activated protein/extracellular signal-regulated kinase kinase/mitogen-activated protein kinase inhibitors interact synergistically with STI571 to induce apoptosis in Bcr/Abl-expressing human leukemia cells. Cancer Res. 2002;62:188–199

☆ Supported by grants from the National Cancer Institute, The Leukemia and Lymphoma Society, Burroughs Wellcome Fund, T. J. Martell Foundation, and the Doris Duke Charitable Foundation.

☆☆ Address reprint requests to Brian J. Druker, MD, Oregon Health & Science University, L592, 3181 SW Sam Jackson Park Rd, Portland, OR 97239.

PII: S0037-1963(03)70042-0

Seminars in Hematology
Volume 40, Issue 1 , Pages 50-58 , January 2003

Article Tools

* Image Usage & Resolution